Bupropion Hydrochloride Sustained Release and Diurnal Enuresis: A Previously Unreported Adverse Effect.

abstract：:The effect of arotinolol, a peripherally acting beta-adrenergic-blocking agent, on postural or kinetic tremor was studied in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Male cynomolgus monkeys (Macaca fascicularis) were treated with three injections of MPTP hydrochloride (0.3...

journal_title：Clinical neuropharmacology

authors： Kuno S,Mizuta E,Nishida J,Takechi M

更新日期：1992-10-01 00:00:00

abstract：RATIONALE:Clobazam (CLB) has proven efficacy against multiple seizure types. Although available in many countries, it is not approved by the US Food and Drug Administration. The objective of this study was to evaluate the usage patterns, efficacy, tolerability, and 1-year retention of CLB in patients with refractory ep...

journal_title：Clinical neuropharmacology

authors： Montenegro MA,Arif H,Nahm EA,Resor SR Jr,Hirsch LJ

更新日期：2008-11-01 00:00:00

abstract：:Midazolam, a potent short-acting benzodiazepine, is a safe and highly effective agent for the control of status epilepticus. Its efficacy in the control of neonatal seizures, however, has not been determined. Six neonates (aged 1-9 days; gestation, 30-41 weeks) developed seizures from a variety of causes. In each case...

journal_title：Clinical neuropharmacology

authors： Sheth RD,Buckley DJ,Gutierrez AR,Gingold M,Bodensteiner JB,Penney S

更新日期：1996-04-01 00:00:00

abstract：BACKGROUND:We investigated the frequencies of the symptoms such as "ataxia, depression, insomnia, anorexia, and pain," that have been reported to be associated with 5-HT1A receptor, and the effect of tandospirone citrate (tandospirone: 5-HT1A agonist) in patients with Machado-Joseph disease (MJD). METHODS:Ten MJD pati...

journal_title：Clinical neuropharmacology

authors： Takei A,Fukazawa T,Hamada T,Sohma H,Yabe I,Sasaki H,Tashiro K

更新日期：2004-01-01 00:00:00

abstract：OBJECTIVES:Our study aimed to identify the association of norepinephrine transporter gene (SLC6A2), synaptosomal-associated protein of the 25-kDa gene (SNAP-25), and latrophilin 3 gene (LPHN3) with osmotic-controlled release oral delivery system methylphenidate (OROS MPH) treatment response. METHODS:One hundred thirty...

journal_title：Clinical neuropharmacology

authors： Song J,Kim SW,Hong HJ,Lee MG,Lee BW,Choi TK,Lee SH,Yook KH

更新日期：2014-09-01 00:00:00

abstract：:A large number of patients with neurosyphilis present dementia with a progressive course and psychiatric symptoms such as depression, mania, and psychosis. Despite prompt and proper antibiotic treatment, the recovery is often incomplete, especially when tissue damage has occurred. We reported a patient with persisted ...

journal_title：Clinical neuropharmacology

authors： Wu YS,Lane HY,Lin CH

更新日期：2015-07-01 00:00:00

abstract：:Four to 10% of patients with Parkinson disease and chronically treated with levodopa undergo an addictionlike behavioral disturbance named dopamine dysregulation syndrome (DDS). This article suggests that patients with Parkinson disease could be especially prone to develop DDS due to the dopamine deficiency and the "p...

journal_title：Clinical neuropharmacology

authors： Linazasoro G

更新日期：2009-01-01 00:00:00

abstract：:The treatment of obesity remains a puzzling challenge because long-term maintenance of weight loss--one of the most suitable goals--is rarely achieved with conventional methods. Among the theoretical measures able to maintain a permanent and bearable constraint to obtain the maintenance of weight loss is long-term (li...

journal_title：Clinical neuropharmacology

authors： Guy-Grand BJ

更新日期：1988-01-01 00:00:00

abstract：:Therapeutic strategies in the treatment of dystonia consist primarily of pharmacologic, surgical, and supportive approaches. Many recent advances have been made in the treatment of dystonia with newer medications, availability of different botulinum toxins, and surgical procedures. However, these treatment modalities ...

journal_title：Clinical neuropharmacology

authors： Goldman JG,Comella CL

更新日期：2003-03-01 00:00:00

abstract：:Botulinum toxin A (BTA) is considered an effective treatment of cervical dystonia. The aim of this prospective, randomized, double-blind study was to compare Botox and Prosigne, a BTA of Chinese origin, with a view to establish the safety, the efficacy, and the equivalence of doses of the 2 formulations in the treatme...

journal_title：Clinical neuropharmacology

authors： Quagliato EM,Carelli EF,Viana MA

更新日期：2010-01-01 00:00:00

abstract：OBJECTIVES:IPX066 is an oral, extended-release capsule formulation of carbidopa-levodopa (CD-LD) available in 4 strengths. The goals of this investigation were to assess the dose proportionality of IPX066 and to study the effects of a high-fat, high-calorie meal and of sprinkling the capsule contents on applesauce on t...

journal_title：Clinical neuropharmacology

authors： Yao HM,Hsu A,Gupta S,Modi NB

更新日期：2016-01-01 00:00:00

abstract：:Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporarily related to the open-label addit...

journal_title：Clinical neuropharmacology

authors： Rosse RB,Kendrick K,Tsui LC,Fay-McCarthy M,Collins JP Jr,Rosenberg P,Wyatt RJ,Deutsch SI

更新日期：1995-08-01 00:00:00

abstract：:The primary objective of this study was to describe the pharmacokinetics of oral pergolide in patients with mild to moderate Parkinson disease using a new high-performance liquid chromatography-tandem mass spectrometry assay. A secondary objective was to investigate the relationship between plasma concentrations and e...

journal_title：Clinical neuropharmacology

authors： Thalamas C,Rajman I,Kulisevsky J,Lledó A,Mackie AE,Blin O,Gillespie TA,Seger M,Rascol O

更新日期：2005-05-01 00:00:00

abstract：:A patient with melanoma and sporadic positive melanuria developed Parkinson's disease. Treatment with levodopa failed to modify tumoral progress. However, during chemotherapy with dacarbazine, the patient experienced a significant impairment to levodopa response. ...

journal_title：Clinical neuropharmacology

authors： Merello M,Esteguy M,Perazzo F,Leiguarda R

更新日期：1992-02-01 00:00:00

abstract：:Glutamate is the predominant excitatory neurotransmitter of the basal ganglia, where it acts on ionotropic and metabotropic receptors. In the best studied of the basal ganglia disorders, Parkinson's disease, there is compelling evidence that the activities of glutamatergic pathways are altered. Of particular importanc...

journal_title：Clinical neuropharmacology

authors： Greenamyre JT

更新日期：2001-03-01 00:00:00

abstract：:In recent studies, disorders of chromatic and achromatic vision in parkinsonian patients have been demonstrated; these could be partially restored after application of L-Dopa. In this study, the effect of a 3-day infusion therapy with amantadine sulphate on color vision was evaluated in 19 parkinsonian patients by use...

journal_title：Clinical neuropharmacology

authors： Büttner T,Kuhn W,Müller T,Patzold T,Przuntek H

更新日期：1995-10-01 00:00:00

abstract：:Venlafaxine (VEN) pharmacokinetics and effects on the brain monoamine output were investigated in the context of experimental hepatic encephalopathy (HE). Systemic VEN (10 mg/kg; subcutaneous) was administered to chronic portacaval shunted (PCS) and sham-operated rats. Their neocortical extracellular levels of 5-HT, 5...

journal_title：Clinical neuropharmacology

authors： Wikell C,Bergqvist PB,Hjorth S,Apelqvist G,Björk H,Bengtsson F

更新日期：1998-09-01 00:00:00

abstract：:Hypereosinophilia is asymptomatic but can induce organ damage, which may cause neurological system abnormalities. We recently encountered a 29-year-old woman with depressive episodes who had eosinophilia as well as hyperventilation attacks, tremor, insomnia, and arthralgia of extremities after receiving paroxetine tre...

journal_title：Clinical neuropharmacology

authors： Yasui-Furukori N,Sato Y,Kato H,Kaneko S

更新日期：2012-01-01 00:00:00

abstract：:Studies assessing the effect of transdermal nicotine in Parkinson's disease (PD) have generated mixed results regarding its efficacy to treat motor and cognitive deficits. These studies generally reported good tolerability in nonsmoking PD patients. The authors report the tolerability data of an open trial with transd...

journal_title：Clinical neuropharmacology

authors： Lemay S,Blanchet P,Chouinard S,Masson H,Soland V,Bédard MA

更新日期：2003-09-01 00:00:00

abstract：:Monoamine oxidase (MAO) inhibitors (MAOIs) provide effective alternative therapy for those patients with major depression who do not respond to tricyclic antidepressants or such related compounds as the selective serotonin reuptake inhibitors. This article reviews studies on the efficacy of both the classical MAOIs an...

journal_title：Clinical neuropharmacology

authors： Nolen WA,Hoencamp E,Bouvy PF,Haffmans PM

更新日期：1993-01-01 00:00:00

abstract：:Data on a twice-daily dosage schedule with moclobemide in the treatment of depression is limited. In this study, moclobemide 150 mg twice daily (b.i.d.) was compared to two different three-times-daily (t.i.d.) regimens with total daily dosages of 300 and 450 mg, respectively, over a 6-week period. The study was random...

journal_title：Clinical neuropharmacology

authors： Gagiano CA,Hart GA,Bodemer W,Schall R

更新日期：1994-01-01 00:00:00

abstract：:Hypothermia is a potentially life-threatening emergency. This article examines the case of a 34-year-old, mentally retarded man who experienced three episodes of hypothermia during recurrent exposure to pipamperone. After the pipamperone dose was largely reduced, no further hypothermic episodes occurred. Nine other ca...

journal_title：Clinical neuropharmacology

authors： Schwaninger M,Weisbrod M,Schwab S,Schröder M,Hacke W

更新日期：1998-11-01 00:00:00

abstract：OBJECTIVE:The purpose of this study is to investigate the safety and efficacy of aripiprazole in first-episode drug-naive patients with schizophrenia. METHODS:A total of 45 patients were enrolled in an open-label 12-week study. Dosing was determined by clinical judgment. The main efficacy measure was the Brief Psychia...

journal_title：Clinical neuropharmacology

authors： Takahashi H,Oshimo T,Ishigooka J

更新日期：2009-05-01 00:00:00

abstract：:The objective of this study was to evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of five fixed doses of ganstigmine (CHF 2819) in patients with probable Alzheimer's disease (AD). This randomized, double-blind, placebo-controlled trial evaluated five dose levels (5, 7...

journal_title：Clinical neuropharmacology

authors： Jhee SS,Fabbri L,Piccinno A,Monici P,Moran S,Zarotsky V,Tan EY,Frackiewicz EJ,Shiovitz T

更新日期：2003-05-01 00:00:00

abstract：BACKGROUND:Recent studies indicate that the traditional Japanese herbal medicine yi-gan san (YGS, yokukan-san in Japanese) may be safe and useful for treating behavioral and psychological symptoms in dementia, borderline personality disorder, neuroleptic-induced tardive dyskinesia, and treatment-resistant schizophrenia...

journal_title：Clinical neuropharmacology

authors： Miyaoka T,Furuya M,Kristian L,Wake R,Kawakami K,Nagahama M,Kawano K,Ieda M,Tsuchie K,Horiguchi J

更新日期：2011-01-01 00:00:00

abstract：OBJECTIVES:We investigated the effects of age on the association between early and eventual responses to paroxetine treatment in patients with major depressive disorder (MDD). METHODS:Eighty-nine patients with MDD were administered paroxetine and completed the 6-week protocol. On the basis of our previous study, we de...

journal_title：Clinical neuropharmacology

authors： Tomita T,Sato Y,Nakagami T,Tsuchimine S,Kaneda A,Kaneko S,Nakamura K,Yasui-Furukori N

更新日期：2015-01-01 00:00:00

abstract：:Successful combination therapy with atypical antipsychotics and selective serotonin reuptake inhibitors has been reported for several psychiatric conditions. However, great attention should be paid to the possible adverse effects. In this retrospective chart review, we focused on the drug-drug interaction of paroxetin...

journal_title：Clinical neuropharmacology

authors： Fukui H,Murai T

更新日期：2002-09-01 00:00:00

abstract：:Palinopsia is an illusory visual phenomenon consisting in the persistence or recurrence of visual images after the exciting stimulus object has been removed. It has been reported in association with parietal and occipital lobe lesions, migraine auras, and related to the use of several drugs and illicit drugs. Here, we...

journal_title：Clinical neuropharmacology

authors： Sierra-Hidalgo F,de Pablo-Fernández E

更新日期：2013-03-01 00:00:00

abstract：:A case of a mentally retarded patient with sporadic paroxysmal dystonia, unresponsive to anticonvulsant therapy, is described. He had a long-standing history of neuroleptic drug intake. Trihexyphenidyl in a total daily dosage of 20 mg totally suppressed the crises. ...

journal_title：Clinical neuropharmacology

authors： Micheli F,Fernandez Pardal M,de Arbelaiz R,Lehkuniec E,Giannaula R

更新日期：1987-08-01 00:00:00

abstract：:Daily 20-mg doses of Copolymer 1 have been shown to significantly decrease the relapse rate in patients with multiple sclerosis (MS). In the present open-label study, patients with relapsing MS were treated with the same dose of Copolymer 1 administered on alternate days. Sixty-eight patients were recruited: fifty-one...

journal_title：Clinical neuropharmacology

authors： Flechter S,Kott E,Steiner-Birmanns B,Nisipeanu P,Korczyn AD

更新日期：2002-01-01 00:00:00